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Abstract
Gradual alterations of cell’s physiology and functions due to age or exposure to
various stresses lead to the conversion of normal cells to senescent cells. Once
becoming senescent, the cell stops dividing permanently but remains
metabolically active. Cellular senescence does not have a single marker but is
characterized mainly by a combination of multiple markers, such as,
morphological changes, expression of cell cycle inhibitors, senescence associated
β-galactosidase activity, and changes in nuclear membrane. When cells in an
organ become senescent, the entire organism can be affected. This may occur
through the senescence-associated secretory phenotype (SASP). SASP may exert
beneficial or harmful effects on the microenvironment of tissues. Research on
senescence has become a very exciting field in cell biology since the link between
age-related diseases, including cancer, and senescence has been established. The
loss of regenerative and homeostatic capacity of the liver over the age is
somehow connected to cellular senescence. The major contributors of senescence
properties in the liver are hepatocytes and cholangiocytes. Senescent cells in the
liver have been implicated in the etiology of chronic liver diseases including
cirrhosis and hepatocellular carcinoma and in the interference of liver
regeneration. This review summarizes recently reported findings in the
understanding of the molecular mechanisms of senescence and its relationship
with liver diseases.
Key words: Senescence; Senescence associated secretory phenotype; Hepatocyte;
Cholangiocyte; Hepatic stellate cell; Cell cycle arrest; DNA damage
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Core tip: The liver is a vital organ for metabolic regulation and plays a major role in the
nutrient utilization of the whole body. Although scientists have paid much attention to
hepatic senescence, the precise mechanisms in, and the contribution of cellular
senescence to liver diseases have yet to be clearly defined. In this review, we have
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summarized the mechanism of senescence in general and in the liver. We have also
discussed whether hepatocellular senescence is beneficial or harmful to the liver in the
light of published findings.
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INTRODUCTION
Definition of senescence
In response to endogenous and exogenous stress, cells in various tissues may enter
into  a  permanent  cell  cycle  arrest.  These  cells  cannot  proliferate  but  remain
metabolically active for an extended period of time and are thus termed as senescent
cells. Conversion of normal cells into senescent cells occurs throughout the life-time of
an organism and plays important roles in tissue homeostasis[1].  In 1961,  Leonard
Hayflick observed that a human fibroblast cell ceased replication after forty to sixty
divisions.  As a  result  of  Hayflick’s  experiments  the limited capacity  for  cellular
division in cell culture was termed as the “Hayflick Limit”. Later it was found that the
cause of the Hayflick Limit was the shortening of telomeres, portions of DNA at the
ends of chromosomes, which slowly erode as cells replicate.
Hayflick and Moorhead first introduced the term senescence to describe the limited
proliferation ability of human fibroblasts in cell culture. However, cells with senescent
properties have been discovered in vivo in many types of tissues and the number of
senescent cells increases with age[1-6]. Initially senescence was thought to be an artifact
in tissue culture with no relevance to the physiology and pathology of an organism.
But subsequent studies have proved the importance of senescence in the biological
processes, such as embryonic development, tissue repair, tumor suppression and
aging[7]. Senescence is now considered as a multistep, dynamic cellular process. When
cells are stimulated by senescence-inducing signals,  such as oncogene activation,
DNA damage, or other stress-mediated signals,  they undergo cell  cycle arrest or
senescence initiation. In the next step, cells with cell cycle arrest undergo chromatin
remodeling,  present  senescence-associated  secretory  phenotype  (SASP),  change
morphology and gain other characteristics of a full-fledged senescence phenotype.
Senescent cells can persist for months[8]. When senescence occurs due to oncogene
activation, cell cycle arrest first happens in an autocrine manner, but SASP factors can
induce paracrine senescence in other cells at a late stage after the immune system is
activated[9,10], thus spreading senescence to neighboring cells across an organ.
There are two hypotheses to explain whether cellular senescence is beneficial or
detrimental to an organism. We can consider senescence as a tumor suppressive or
anti-cancer process as the senescent cells cannot divide. Therefore, senescence may be
good for  an organism. On the other hand,  cellular  senescence may cause loss  of
regenerative capability of an organ such as the liver. In this respect, it is considered a
deleterious process for an organism as it may affect the function and tissue renewal[11].
In either case, more in vivo studies on the mechanisms are needed.
Characteristics of senescence
The senescence phenotype is  very stable,  unresponsive to mitogenic stimuli  and
resistant to apoptosis[11].  The telomere dysfunction in normal cells can lead to the
conversion  to  replicative  senescent  cells.  Important  stimuli  like  oncogene  over-
activation,  global  DNA  damage,  and  oxidative  stress  may  act  individually  or
synergistically to trigger senescence in normal cells[12]. When cells undergo senescence,
they are characterized by alterations in morphology, lysosomal activity and gene-
expression. These include expression of cell cycle inhibitors, such as p15INK4B, p16INK4A,
and p21Cip1, activation of DNA damage response, alterations of chromatin structures
and induction of SASP. Usually senescent cells exhibit enlarged, flat morphology and
are frequently multi-nucleated[13]. For example, the report from Aravinthan et al[14]
showed that senescent hepatocytes, which overexpress p21Cip1, can be characterized
with larger nuclei, compared to non-senescent hepatocytes.
Senescent cells express a higher level of lysosomal β–galactosidase gene (GLB1) and
show an increased β–galactosidase activity at a suboptimal pH of 6.0 (optimal pH
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level is 4-4.5), compared to normal cells[3,15]. Of note, as a single cell based assay, the β-
galactosidase activity assay is the most commonly used analysis for the senescence
property of cells in vitro or in vivo[16]. The cumulative effect of various stresses on the
small population of affected cells may lead to conversion of a homogenous population
of senescent cells[12].
SASP and senescence
Senescent cells can secrete a large number of proinflammatory cytokines, chemokines,
growth factors and proteases that may have a variety of effects on neighboring cells.
This  phenotype  of  senescent  cells  is  known  as  senescence-associated  secretory
phenotype (SASP). Senescent cells are highly secretory and they execute a diverse set
of functions mediated by SASP[17]. As senescent cells are viable and actively secreting
cells, they have a profound influence on the surrounding cells. SASP affects senescent
cells and their microenvironments in both autocrine and paracrine fashions. SASP
factors are highly dynamic in expression and the composition changes over the period
of  senescence.  This  change  in  the  composition  of  SASP  in  senescent  cells  may
determine whether the effect is beneficial or harmful in the respective organs[17]. The
mechanisms of the initiation and regulation of SASP and its influence in inflammation
and disease processes have not been fully elucidated yet.
SIGNALING PATHWAYS IN SENESCENCE
The reactive oxygen species (ROS) is considered as one of the main activators of
senescence  cells[18,19].  The imbalanced ROS may cause  oxidative  stress  and DNA
damage, leading to the activation of DNA damage response in the affected cells.
Signaling pathways that control cell cycle arrest
The p53 and Rb signaling pathways may become activated in response to extrinsic
and  intrinsic  stressors,  including  DNA  damage.  p53  and  Rb  can  affect  tran-
scriptionally both upstream regulators and downstream effectors in the senescence
pathway[20].  The inactivation of  either p53 or Rb prevents or  significantly delays
senescence[21] (Figure 1). ATM and ATR, as well as their downstream targets, Chk1
and  Chk2,  become  activated  during  DNA  damage,  which  in  turn  activate  p53.
Activated p53 is considered as one of the main players in converting normal cells to
senescent  cells.  The  phosphorylated  form  of  p53  is  the  essential  contributor  of
replicative senescence in human fibroblast[22]. Acetylation of p53 at Lys161/Lys162 is
also  important  for  cell  cycle  arrest  and  senescence[23].  Once  p53  is  activated  by
posttranslational modification, it in turn activates its transcriptional target, p21Cip1
(CDKN1A). p21Cip1 is the inhibitor of Cyclin E/CDK2 complex and it promotes cell
cycle arrest at G1/S phase of cell cycle (Figure 1). Of note, p21Cip1 can be activated by
both p53-dependent and p53-independent mechanisms[24].
Retinoblastoma protein (Rb) is a tumor suppressor and a well-established cell cycle
regulator. Rb is expressed in all tissues and controls cell cycle progression through
interactions  with  the  E2F  family  of  transcription  factors[20,25].  Other  Rb  family
members,  namely, p107 and p130, also play active and important role in driving
senescence independently of Rb[26]. p21Cip1 has been found to be both a positive and
negative regulator of Rb by regulating either Rb phosphorylation or degradation,
respectively[27].  p16INK4A  (CDKN2A) inactivates  Cyclin-dependent  kinases,  which
phosphorylate  Rb,  and Rb phosphorylation  status  in  turn  has  an  impact  on  the
expression of p16INK4A.  In normal cells,  Cyclin D and Cyclin E bind to CDK2 and
CDK4/6,  respectively,  since  p21Cip1  and  p16INK4A  level  remain  at  the  basal  level.
Hyperphosphorylation of Rb permits the E2F factor to participate in the production of
replication proteins and hence cell cycle progress. But a higher level of either p16INK4A
and/or p21Cip1  can keep Rb in the hypophosphorylated state so that E2F remains
bound with it.  Therefore,  cell  cycle is  arrested,  which ultimately lead to cellular
senescence (Figure 1).
Another cell cycle inhibitor, CDKN3 is a phosphatase and dephosphorylates Rb
thus ensuring that cell cycle progression is blocked. Thus, CDKN3 is considered as an
important contributor to cellular senescence[28]. CDKN3 can also interact with Mdm2
and form a complex with p53 and Mdm2. Once the complex is formed, p53 losses its
ability to induce p21Cip1[29,30].
G1-phase cell cycle arrest can also be induced by transforming growth factor-beta
(TGFβ)[31]. TGFβ can keep Rb in hypophosphorylated state, suggesting that it may
suppress Rb phosphorylation and thereby interfering with cell cycle progression[32].
p15INK4B(CDKN2B), a homologue of p16INK4A, is activated by TGFβ, acts on CyclinD-
CDK4/CDK6 complex and contributes to cell cycle arrest, and hence to senescence[33]
(Figure 1). Since p15 INK4B  and p16INK4A  have a common mode of action, in a tissue
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Figure 1
Figure 1  Stress-induced senescence. Both external and internal stresses can induce DNA damage and the
activation of p16INK4A and/or p15INK4B. DNA damage can activate p53 ataxia telangiectasia mutated (ATM) and ATM
and RAD3-related (ATR) pathway. Activated p53 induces p21 Cip1 expression. Expression of p21Cip1 can also be
regulated by p53-independent mechanisms. The Cyclin dependent kinases activate Rb but are inhibited by p15INK4B/
p16INK4A and p21Cip1 which leads to cell cycle arrest and senescence. The senescent cells express senescence-
associated secretory phenotype (SASP). The SASP factors may induce senescence in neighboring cells in a
paracrine fashion. ATM: Ataxia telangiectasia mutated; SASP: Senescence-associated secretory phenotype.
where either  one does  not  express,  the  other  can possibly  compensate  the  func-
tionality.
Signaling pathways that regulate SASP
The connection between senescent cells and the immune system is mediated by SASP.
The  inflammation  signature  of  SASP  include  chemokines,  cytokines  and  other
immune  modulators.  SASP  is  regulated  at  multiple  levels’  such  as,  chromatin
modification,  transcription,  translation,  mRNA  stability  and  secretion[34].  The
autocrine and paracrine positive feedback loops also regulate the signaling of SASP.
Most senescent cells express multiple cytokines such as IL-8, CCL2 (MCP-1), CCL7
(MCP-3), CCL8 (MCP-2), CCL13 (MCP-4), CCL3, CCL16, CCL20, CXCL1, CXCL2,
CXCL3 ect[35,36].  The most  characterized SASP components  include multiple  pro-
inflammatory cytokines, such as interleukin-1 (IL-1), and interleukin-6 (IL-6). IL-1 and
IL-6 produced in senescent epithelial and fibroblast cells are capable of inducing
cellular senescence in adjacent cells. SASP helps spreading senescence phonotype
among nonsenescent cells by creating an inflammatory environment in tissues. The
knock-down of IL-6 and IL-8 receptors IL-6R and CXCR2, respectively,  prevents
senescence[34].
SASP is  induced and regulated  by  several  signaling  pathways  leading  to  the
activation  of  the  nuclear  factor-κB  (NF-κB)  and/or  CCAAT/enhancer-binding
protein-β (C/EBPβ). In senescent cells, activated NF-κB and C/EBPβ regulate the
expression of  SASP factors  by controlling,  mainly  at  the  transcription level,  the
inflammatory SASP molecules, IL-1α, IL-6 and IL-8. These inflammatory SASP factors
can enhance SASP signaling through activating NF-κB , and C/EBPβ in an autocrine
feed-forward fashion[37,38] (Figure 2).
NOTCH signaling pathway:  This pathway has been implicated as an important
regulator of  SASP. Works from Hoare et  al[39]  suggested a global upregulation of
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Figure 2
Figure 2  Senescence-associated secretory phenotype signaling pathways. Nuclear factor kappa light chain
enhancer of activated B cells can be activated via multiple signaling pathways such as the GATA binding protein 4,
cyclic GMP-AMP synthase-stimulator of interferon genes, and nicotinamide adenine dinucleotide -nicotinamide
phosphoribosyltransferase NAD+-NAMT pathways, which lead to the expression of senescence-associated secretory
phenotype (SASP) proteins. SASP can be positively regulated through C-X-C motif chemokine receptor 2, or
negatively by NOTCH via CCAAT-enhancer-binding proteins. SASP can induce senescence in both autocrine and
paracrine manners. SASP can be anti-tumorigenic in the early phase of senescence, but can be pro-tumorigenic in
the late phase of senescence. NF-κB: Nuclear factor kappa light chain enhancer of activated B cells; GATA4: GATA
binding protein 4; cGAS-STING: Cyclic GMP-AMP synthase-stimulator of interferon genes; SASP: Senescence-
associated secretory phenotype; CXCR2: C-X-C motif chemokine receptor 2; C/EBP: CCAAT-enhancer-binding
protein.
NOTCH1  accompanied  by  dynamic  alterations  of  its  downstream  activity  in
senescence. They also proposed NOTCH1 as a master regulator of SASP composition
via a temporal and functional switch between two different secretomes, TGFβ and
pro-inflammatory cytokines through down-regulation of C/EBPβ.
The NOTCH1 was shown to be upregulated in cells undergoing oncogene-induced
senescence (OIS), which caused upregulation of TGFβ in the first phase of senescence.
The inhibition of NOTCH signaling substantially reduced TGFβ induction in OIS
cells.  The  inhibition  of  TGFβ  in  NOTCH1-driven  senescent  cells  prevented  the
upregulation of the TGFβ-targeted cell cycle inhibitor, p15INK4B. In addition, Hoare et
al[39] found that NOTCH1 negatively regulated C/EBPβ but had no effect on NF-κB
pathway in the later phase of senescence. The overexpression of activated Notch1
receptors (N1ICD - NOTCH1 intracellular domain) inhibited the ability of C/EBPβ to
induce IL-1, IL-6 and IL-8[39].  Moreover, Hoare et al[39]  found that inhibiting Notch
signaling accelerated clearance of senescent cells in the liver.  Therefore, NOTCH
signaling  pathway  may  be  associated  with  a  complicated  mechanism  of  SASP
regulation. But the key questions that remain to be addressed are: (1) Which factor(s)
involved in the switching from NOTCH1-TGFβ to NOTCH1-C/EBPβ; (2) What the
cross-talk is between NOTCH1-mediated C/EBPβ and NF-kB regulation in senescent
cells.
cGAS-STING pathway: cGAS (cGMP-AMP synthase) is a cytosolic DNA sensor and
it is activated in response to cytosolic DNA. This activated cGAS binds and activates
Stimulator of Interferon Gene (STING). During cellular senescence, the organization
of  chromatin  changes  and undergoes  degeneration.  The integrity  of  the  nuclear
envelope  is  disrupted  due  to  the  loss  of  the  nuclear  lamina  protein  Lamin  B1.
Eventually, small chromatin fragments migrate from nucleus to cytoplasm to become
cytoplasmic chromatin fragments (CCF) in senescent cells[40]. cGAS can be activated by
any double-stranded DNA irrespective of the sequence[41]. Therefore, CCF from the
senescent cells can activate cGAS-STING pathway and upregulate SASP expression
via inducing type-1 interferons (IFN-1). The cGAS-STING signaling pathway drives
the production of inflammatory SASP cytokines through type I interferon via IRF3
and proinflammatory responses via NF-κB[40,42], thereby facilitating senescence. Gluck
et al[43]  demonstrated that cGAS deficiency in the liver abrogated the induction of
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senescence in hepatocytes, which suggests the importance of cGAS in the process of
senescence in vivo.
Cecco et al.[44]  showed that in oncogene-induced senescence and stress-induced
premature senescence, activation of retrotransposable element, L1, and IFN-1 occur in
the late phase. They found three factors that caused L1 activation, RB1, FOXA1 and
TREX1.  RB1  expression  was  declined  in  senescent  cells  but  was  enhanced  in
proliferating cells. Upregulation of FOXA1 and downregulation of RB1 and TREX1
were found to be associated with L1 activation and stabilization. The activation of L1
ensured a strong activation of INF-1 response in senescent cells. In addition, when the
cGAS-STING pathway was disrupted, the INF-1 response was inhibited and SASP
response such as the induction of CCL2, IL-6, and MMP3 were downregulated in the
late phase of senescent cells.
NAD+-NAMT  pathway:  NAD+  and  the  rate-limiting  enzyme  of  its  synthesis,
nicotinamide phosphoribosyltransferase (NAMPT), have a critical role in ageing and
cancer[45-47]. Recently, Nacarelli et al[47] demonstrated a mechanism of SASP regulation
that involves these factors and HMGA proteins HMGA1 and HMGA2[47].  HMGA
proteins are known to regulate the chromatin structure and to promote senescence[48].
Now, these proteins are found to regulate NAMPT gene expression by binding at the
enhancer element during oncogene-induced senescence of fibroblasts[47].  NAMPT
upregulates the expression of proinflammatory SASP fators such as IL-1β, IL-6 and IL-
8, which are dependent on the enzymatic activity of NAMPT. This proinflammatory
activity are regulated by increased NAD+/NADH ratio. Nacarelli et al[47] have also
demonstrated that increased NAD+/NADH ratio causes suppression of AMPK, which
interferes  with  p53-mediated  inhibition  of  p38  MAPK.  p38  MAPK  controls  the
transcriptional  activity  of  NF-κB  by  regulating  acetylation  of  p65.  The  NF-κB
mediated proinflammatory activity is therefore enhanced.
In addition to HMGA proteins, another high mobility group protein, HMGB1, has
been implicated in the senescence and SASP. Davalos et al[49] reported the existence of
a relationship between HMGB1 and senescence. They found that altered expression of
HMGB1 induced senescence in a p53-dependent manner in fibroblasts. Exogenous
HMGB1 treatment activated NF-κB activity and IL-6 secretion whereas depletion of
HMGB1 attenuated the senescence phenotype. The disruption of normal HMGB1
levels can induce a p53-dependent cell cycle arrest. Interestingly, secreted HMGB1 is
essential  for  optimal  secretion  of  IL-6  and  MMP-3,  both  are  important  SASP
components.
Other pathways: The other known regulators of SASP are bromodomain containg
protein 4 (BRD4), lysine methyltransferase MLL1 and G9A[50].  The recruitment of
BRD4 to senescence-activated enhancers located adjacent to SASP genes is probably
required  to  induce  SASP [51].  But  the  upstream  signaling  that  regulate  these
transcriptional  activators  are  not  completely  known.  SASP  helps  spreading
senescence  phonotype  among  nonsenescent  cells  by  creating  an  inflammatory
environment in tissues.
For  SASP  regulation,  mTOR  plays  an  important  role  as  well.  The  4E-BP1  is
phosphorylated by mTOR.  It  is  a  repressor  of  translation of  mRNA. In  order  to
regulate SASP, 4E-BP1 represses IL-1α and MAP kinase-activated protein kinase 2[52].
The degradation of mRNA of proinflammatory SASP factors is associated with a RNA
binding protein,  zinc  finger  protein  36L1 (ZFP36L1);  and MAP kinase-activated
protein kinase 2  inhibits  ZFP36L1[34].  By regulating the stability of  SASP mRNA,
mTOR regulates SASP in senescent cells.
Autophagy and senescence
Autophagy  is  a  highly  regulated  cellular  program  responsible  for  recycling
intracellular proteins and damaged/nonfunctional organelles. Autophagy was found
to be activated in senescence in human fibroblasts due to the negative feedback of
mTOR pathway[53]. A number of genes (e.g., Ulk3 and LC3) associated with autophagy
are upregulated in senescent cells and inhibition of autophagy essential genes like
Atg5  or  Atg7  caused  interference  of  senescence  phenotype  including  SASP[53].
Reciprocally, Kang et al[54] showed that knockdown of autophagy essential genes such
as  Atg7,  Atg12  or  lysosomal  associated  membrane  protein  2  (LAMP2)  caused
senescence in human fibroblasts. This senescence pathway was found to be ROS and
p53-dependent. In contrast, Garcia-Prat et al[55] demonstrated that muscle stem cells
maintain  a  reversible  quiescence  state  and do not  enter  to  senescence  when the
autophagy  mechanism  is  active.  This  group  showed  that  the  muscle  stem  cells
underwent senescence if  autophagy was defective and restoration of  autophagy
prevented senescence in satellite cells. Therefore, autophagy may both induce and
prevent senescence, which may be dependent on cell type or the type of experimental
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model. However, it is still an open question as to whether autophagy is necessary for
senescence to occur or it inhibits the senescence process.
Kang et al[56] reported that a transcription factor, GATA4 played an important role
in  the  cellular  senescence  mechanism.  This  group  suggests  that  GATA4  is  a
senescence  and SASP regulator.  In  normal  cells,  GATA4 binds  to  an autophagy
adaptor, p62, whichis eliminated by the selective autophagy process. This autophagy
process is suppressed when senescence is induced. DNA damage activates ATM and
ATR kinases, which inhibit p62-mediated GATA4 degradation. The stabilized GATA4
then  activates  NF-κB  inducers  TRAF3IP2  and  IL-1A.  NF-κB,  one  of  the  master
regulators of senescence, initiates and maintains SASP, and facilitates senescence. The
GATA4 activation is found to be independent of p53 and p16INK4A but is dependent on
ATM and ATR kinases. This finding suggests that GATA4 may represent a separate
branch  of  DNA  damage  repair  response  that  induces  SASP  and  hence  favors
senescence.  Kang et  al[56]  has  suggested a  clarification on the  argument  whether
autophagy induces or inhibits senescence. Selective autophagy prevents cells from
undergoing senescence by limiting GATA4 level when senescence-inducing stimuli,
such as irradiation are given but later general autophagy lead to cellular senescence[57].
At least, one more member of the GATA family, GATA6, has been implicated in the
senescence mechanism. Perlman et al[58] reported that GATA6 overexpression could
upregulate  the expression of  p21Cip1  so  that  the proliferation of  vascular  smooth
muscle cells and fibroblasts were inhibited. Zhang et al[59] suggested the existence of a
direct  relationship  between  autophagy  and  GATA6.  Autophagy  decreased
accumulation of GATA6 and p62 was found to be a negative regulator of GATA6
accumulation. Zhang et al[59] also determined the relationship between an antimalarial
drug, dihydroartemisinin (DHA) and GATA6, and their contribution to the hepatic
senescence. DHA treatment enhanced the expression of p53, p21Cip1 and p16INK4A and
induced senescence in hepatic stellate cells (HSCs) in rat livers. GATA6 accumulation
further accelerated the expression of p53 and p16INK4A  in DHA-treated livers and
promoted senescence. The knock-down of GATA6 by siRNA significantly reduced
DHA-induced upregulation of p53 and p16INK4A, and thereby the senescence.
SENESCENCE IN THE LIVER
The  detailed  mechanism  and  biological  function  of  cellular  senescence  in  liver
diseases have not been fully elucidated. But meaningful progresses have been made
in this field. Senescence can adversely affect liver functions, cellular viability and
tissue regeneration under pathological conditions[60]. Senescence in hepatocytes is well
documented  in  different  liver  diseases  such  as  cirrhosis [61,62].  Senescence  in
cholangiocytes[60,63,64] is also known to occur in such biliary diseases as primary biliary
cholangitis (PBC) and primary sclerosing cholangitis (PSC). Senescence in HSCs has
been reported in fibrosis[65].
Mouse models to study liver cell senescence
There are various mouse models developed to study senescence-associated liver
diseases. Demaria et al[66] developed a mouse model named p16INK4A-3MR to visualize
and to eliminate senescent cells in vivo.  The promoter of p16INK4A  was used in this
model to express a fusion protein, composed of luciferase, red fluorescence protein
(RFP) and herpes simplex virus 1 thymidine kinase.  This viral  thymidine kinase
converts ganciclovir (GCV) into an apoptosis inducer. GCV treatment induces p53
accumulation and surges cell surface expression of CD95 and tumor necrosis factor
receptor. Utilizing the p16INK4A-3MR mice and imaging, researchers can investigate a
vigorous, but transient, upsurge in senescent cells in vivo.
AhCre+Mdm2 f l/f l  mice [9]:  Murine  Double  Minute  2  (MDM2)  interferes  the
transcriptional activity of p53 and guides degradation of p53 through ubiquitination.
The disruption of the p53–MDM2 interaction by knocking out MDM2 genetically
leads to p53-mediated cell-cycle arrest through inducing the activation of cell cycle
inhibitor, p21Cip1[67]. Deletion of Mdm2 causes upregulation of p53 and thus p21Cip1.
The AhCre system allows expression of Cre recombinase in hepatocytes in response to
β-naphthoflavin, which in turn deletes the floxed Mdm2. This AhCre+Mdm2fl/fl mouse
model  induces  p21Cip1-dependent  hepatocellular  senescence  conditionally[9].  The
rescue of growth arrest may be achieved by crossing the AhCre+Mdm2fl/fl  mouse
strain to p21Cip1-deficient mouse strain.
K19-Mdm2f/ftdTomLSL[60]: In this mouse model, Mdm2 can be conditionally deleted
in cholangiocytes as the Cre recombinase expression is under the control of Krt19
promoter.  This  model  exhibits  features  of  biliary  diseases  upon  induction  of
senescence in cholangiocytes. The Cre activity in senescent cholangiocytes can be
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monitored following the expression of tdTomato[60].
Mdr2(Abcb4)(-/-)  mouse model  is  useful  for  the study of  chronic biliary liver
disease.  The  mdr2  gene  encodes  a  membrane  protein  that  transports
phosphatidylcholine. mdr2-deficient mice are unable to secrete phosphatidylcholine
into the bile by hepatocytes which leads to cholestatic liver disease. Researchers have
used this model to study senescence in cholangiocytes and fibrosis in the liver[68-70].
Senescence-accelerated  mouse  prone8  (SAMP8)  is  widely  studied  for  aging
mechanism, but is also useful for the study of liver diseases because of its phenotype
of liver dysfunction[71]. The SAMP8 mouse strain exhibits an oxidative stress-induced
age-related  phenotype  and  severe  mitochondrial  dysfunction  related  liver
pathology[72].
Senescence in hepatocytes
The function and the regenerative capacity of the liver deteriorate with age[73]. The
accumulation  of  reactive  oxygen  species  (ROS)  during  aging  could  lead  to  a
significant level of oxidative stress. A number of studies have suggested a causative
connection between cellular injury and oxidative stress in aged individuals[74,75]. Intano
et al[76] reported that DNA damage could be caused by ROS and the repair response
was slowed down in aged mouse hepatocytes. ROS and DNA damage trigger cells to
overexpress  cell  cycle  inhibitors  and  halt  proliferation  of  the  damaged cells  by
inducing senescence. The liver can repair and regenerate normally if the damage is
mild.  But  when  the  degree  of  damage  to  the  liver  is  severe,  hepatocytes  lose
regenerative capacity, and undergo necrosis, apoptosis or senescence[11,77].
Hepatocellular senescence can cause remarkable changes in tissue homeostasis, and
microenvironment through SASP, which may lead to fibrosis and hepatocellular
carcinoma. In the early stage of liver diseases, hepatocellular senescence may serve as
a protective role by blocking proliferation of affected or injured liver cells. Therefore,
the risk for these affected cells to be transformed to cancer cells would be reduced. But
at the later stage of the diseases, senescent cells secrete SASP factors with an abnormal
level of proinflammatory cytokine/chemokines, such as CCL2, and TGFβ, which can
promote  the  conversion  of  non-senescent  cells  to  senescent  cells  in  a  paracrine
manner. Rudolph and DePinho have hypothesized that chronic liver injury causes
progressive  and  repetitive  liver  damage  and  regeneration,  which  leads  to
accumulation of shorter telomeres in hepatocytes. This in turn may lead to hepa-
tocellular senescence and ultimately cirrhosis[78]. In addition, Wiemann et al[62] showed
that telomere shortening and hepatocellular senescence were positively correlated
with progression of  fibrosis  in human cirrhosis  samples,  which denoted hepatic
senescence as a general marker of cirrhosis.
The accumulation of fat in hepatocytes can promote telomere shortening and DNA
damage, which may be mediated by oxidative stress. The critically shorter telomere
and damaged DNA may induce senescence in hepatocytes[11,14]. Aravinthan et al[14]
demonstrated that hepatocytes in non-alcohol-related fatty liver disease (NAFLD)
could enter the senescent state after they overexpressed p21Cip1, and presented a larger
nuclear  area  and  γ-H2AX  positive  foci.  The  presence  of  hepatocyte  senescence
positively correlated not only with the fibrotic stage of the liver but also with the
diabetic state associated with NAFLD.
Any repetitive wave of insult that can cause damage to hepatocytes such as alcohol
intake,  hepatitis  viral  infection,  immune disorder  or  autophagy deficiency,  may
compromise liver regeneration and promote senescence in hepatocytes and other
types of cells[64]. The normal liver contains a basal level of senescent hepatocytes (3%-
7%),  but  in  chronic  hepatitis  and  cirrhosis  the  liver  may  exhibit  50%-100%  of
hepatocytes in senescence[61,62]. The generation of fibrotic scars in cirrhosis is thought
to be the consequence of hepatocyte senescence, which may be used as a marker for
cirrhosis[62].
Teoh  et  al[79]  reported  the  induction  of  p53,  p21Cip1  and  p16INK4A  in  senescent
hepatocytes  during  chronic  liver  diseases  but  the  detailed  mechanism  was  not
studied. Recently Bird et al[9]  published a seminal article showing that acute liver
injury  could  also  induce  hepatocyte  senescence.  Using  a  hepatocyte  specific
senescence  induction  model  (AhCre-Mdm2 f l/fl)  they  found  that  hepatocytes
undergoing cell-autonomous senescence can transfer senescence properties to normal
hepatocytes via a SASP factor, CCL2, which stimulates the production of TGFβ from
hepatic macrophages.
The TGFβ pathway was found to be activated in senescent hepatocytes in human
fulminant liver failure. The targets of TGFβ pathway, SMAD7 and pSMAD2/3, were
upregulated in hepatocytes near the necrotic  area during acute liver  injury.  The
interference of monocyte recruitment with an anti-CCL2 antibody in this model led to
reduction of senescence spreading from senescent hepatocytes to normal hepatocytes,
and enhanced hepatocyte proliferation. This finding suggests that TGFβ and CCL2
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can work together in a non-cell-autonomous senescence pathway. The inhibition of
TGFβ-TGFβ-R1 interaction by specific inhibitors or the depletion of macrophages by
Liposomal  Clodronate  reduced  senescence  progress  and  enhanced  liver
regeneration[9]. This study thus suggests that the senescence process in acute liver
injury may be therapeutically manageable.
Senescent hepatocytes can recruit  and activate immune cells  using their  SASP
property. The activated immune cells can remove senescent hepatocytes, which is
termed as ‘‘senescence surveillance’’, hence preventing malignant transformation[80,81].
Hepatic senescence harboring additional mutations like, p53 mutation, can cause
aggressive hepatocellular carcinoma (HCC)[82]. Restoration of p53 in liver tumors can
activate immune cell-mediated clearance of senescent tumor cells[83,84]. Kang et al[80]
found  that  CD4+  T  cells  clear  senescent  hepatocytes  with  the  help  of  activated
monocytes/ macrophages, which also suggested to the importance of senescence
surveillance as an antitumor barrier for the HCC.
Senescence in cholangiocytes
The existence of senescent cholangiocytes and their potential deleterious effects in
biliary  diseases  (PBC  and  PSC)  have  been  described [85 ,86].  To  have  a  better
understanding of the detailed mechanism of cellular senescence in cholangiopathies,
an in vivo model (K19-Cre-Mdm2f/f)[60] was recently created to study the mechanism of
cholangiocyte mediated biliary senescence in the liver by conditionally activating
senescence in cholangiocytes. The cell-autonomous senescence, where the induction
of p21Cip1 and p16INK4A are dependent on p53 induction in cholangiocytes, results in the
conversion  of  normal  hepatocytes  of  close  proximity  into  non-cell-autonomous
senescence, where the induction of p21Cip1 and p16INK4A are independent on p53[60]. As
in  the  AhCre-Mdm2fl/fl  model  this  paracrine  senescence  was  found to  be  TGFβ-
dependent as the blocking of TGFβ signaling pathway partially interfered with the
paracrine senescence effect. The involvement of other SASP factors in addition to
TGFβ may need to be explored in additional details.
Both  studies  by  Ferreira-Gonzalez  et  al[60]  and  Bird  et  al[9]  have  indicated  the
importance of TGFβ in the transmission of senescence properties from senescent cells
to otherwise normal cells. TGFβ has been shown to be involved in the liver disease
progression from injury to hepatocellular carcinoma[87].  Therefore, TGFβ via  small
molecule inhibitors could be a valuable therapeutic target to treat cholangiopathies
and hepatocellular injury and preventing senescence-associated tumorigenesis.
In cholestatic liver diseases and cholangiopathies, the bile acid (BA) secretion can
be defective and bile acids may not reach to intestine, which may cause accumulation
of  bile  acids  in  the  liver,  and  cholestatic  liver  injury,  which  in  turn  can  induce
senescence  in  liver  cells[88,89].  Whether  a  specific  BA  species  can  directly  cause
senescence  is  not  known.  In  vitro  treatment  of  bile  duct  epithelial  cells  with
deoxycholic acid (DCA) and lithocholic acid (LCA) could not induce SASP. BA may
induce senescence in other cells, such as HSCs.
Senescence in HSC
HSCs are in quiescent state in normal healthy livers but become activated following
liver injury. Activated HSC play an important role in liver fibrosis. There are three
possible fates for the activated and fibrogenic HSC: (1) Apoptosis, to limit the HSC
involvement in extracellular matrix (ECM) deposition; (2) Reversal from the activated
status to quiescence; and (3) Senescence, to limit the degree of fibrosis in the liver.
Multiple inducers of senescence in HSC have been reported, including IL-22, CCN1
(CYR61), retinoic acid, and Substance P ( SP)[69,90].
Hepatocellular  fibrosis  often results  from the excessive deposition of  ECM by
activated  stellate  cells.  The  general  concept  is  that  senescent  hepatocytes  are
associated with fibrosis, impaired liver function and increased mortality. On the other
hand, Krizhanovsky et al[65] reported that in response to liver injury, activated HSC
initially proliferated and contributed to ECM deposition. However, senescent HSC
could limit the extent of fibrosis. Moreover, they found that if HSCs were deficient in
key senescent genes in the p53 or Rb pathways, these cells continued to proliferate
and secreted excessive ECM. These finding suggest that senescent HSCs are probably
beneficial for the injured liver but the senescent hepatocytes are not.
A  secondary  bile  acid,  DCA  can  induce  SASP  in  HSC[91].  The  enterohepatic
circulation of DCA seemed important for the senescence of HSC. DCA can induce
DNA damage by upregulating ROS, which may lead to senescence in HSC but the
underlying  mechanism  is  unclear.  It  is  not  known  if  the  bile  acids  can  induce
senescence in other liver cells.
When HSC proliferate, they secrete molecules that form ECM such as collagens
(e.g., Col1A) and matrix metalloproteins (MMPs). In acute liver injury, senescent HSC
may have antifibrotic effects by secreting matrix metalloprotenases that digest MMPs
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and collagens. However, senescent cells of other origins (non-HSC) can express matrix
metalloprotenase inhibitors, which would promote fibrosis by antagonizing the effect
of senescent HSC. Therefore, detailed studies are required to understand the balance
between fibrogenic and non-fibrogenic SASP in senescent HSC and in senescent non-
HSC.
CONCLUSION
An increasing number of research on hepatocellular senescence have indicated the
importance and significance of the senescence in the liver. The detailed mechanisms
of  hepatic  senescence  are  yet  to  be  fully  determined.  Exploring  the  regulatory
mechanisms of SASP discussed above in the liver will provide an important insight to
fight  against  hepatic  inflammation,  fibrosis  or  cancer  in  the  liver  tissues.
Understanding the molecular mechanisms of cellular senescence in liver diseases will
help  to  develop  important  tools  for  better  diagnosis  and  treatment  of  the  liver
diseases.
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